Status:
UNKNOWN
The Multicentic Trial in Fertility-sparing Treatment and Ovarian Preservation Management for Early Endometrial Cancer
Lead Sponsor:
Min Wang
Collaborating Sponsors:
First Hospital of China Medical University
Conditions:
Endometrial Cancer
Eligibility:
FEMALE
21-65 years
Phase:
NA
Brief Summary
Through multicenter, prospective, randomized, controlled clinical studies comparing different treatment options (fertility-sparing surgery and ovarian preservation surgery and radical surgery)therapeu...
Detailed Description
Patients eligible for enrollment are selected and divided into three groups randomly, including fertility group,ovarian preservation group and endometrial cancer radical surgery group. Take interventi...
Eligibility Criteria
Inclusion
- Premenopausal women, age ≤ 50 years
- Surgical curettage / hysteroscopic pathology confirmed, endometrioid adenocarcinoma G1/G2 (including well-differentiated, high-medium and middle-differentiation);
- Clinical consideration of IA (\<1/2 muscle infiltration);
- First-time treatment
- The subject (or his legal representative) must understand the nature of the study and sign an informed consent form.
Exclusion
- At the same time participate in other clinical trials;
- Can not tolerate surgery;
- Ovarian suspicious metastasis;
- Have a family history of ovarian cancer;
- Incorporate other malignant tumors;
- Preoperative CA125 abnormal persons
Key Trial Info
Start Date :
January 10 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT03804463
Start Date
January 10 2019
End Date
December 31 2021
Last Update
January 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shengjing Hospitaol of China Medical University
Shenyang, Liaoning, China, 110004